Cogstate Competitors

NeuroFlow helps risk-bearing healthcare organizations improve outcomes and cost of care in complex populations by surfacing and supporting behavioral health needs that typically go undetected and under-addressed. Across payors, providers, and the federal government, NeuroFlow’s scalable technology and analytics capabilities empower organizations with actionable intelligence from real-time data collection and risk stratification, enabling them to manage populations in a financially sustainable way. Powered by deep expertise in whole-person care, NeuroFlow offers a path to risk predictability and proactive care that helps overcome the systemic challenges in today’s healthcare ecosystem.

Cambridge Cognition Plc (AIM: COG) is the neuroscience technology company developing provides scientifically validated digital cognitive measurement, to advance brain health research, treatment, detection and outcomes worldwide. Backed by over 40 years of research, 3,600+ peer-reviewed publications and use in more than 600 clinical trials, our digital and voice-based assessments are trusted by academics, clinical teams, healthcare professionals and consumers to detect meaningful changes in cognition and enable more informed decision-making.

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.